

## WilmerHale Represents Placement Agents in BiomX Acquisition-Related Private Placement Financing

MARCH 6, 2024

BiomX Inc., a publicly traded clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, [announced](#) that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc., a privately held clinical-stage company advancing therapies to treat multi-drug resistant infections. Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive purchase agreement providing for the sale by BiomX of shares of newly created non-voting convertible preferred stock and warrants to purchase shares of BiomX common stock in a private placement to certain institutional accredited investors. The private placement is expected to result in gross proceeds to BiomX of \$50 million. The proceeds from the private placement are expected to advance the combined company's two lead product candidates through Phase 2 clinical readouts.

A WilmerHale team including [Glenn Pollner](#) and [Leigh Krafchek](#) is representing the placement agents, RBC Capital Markets and Laidlaw & Company (UK) Ltd., in the private placement.